S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
ASML’s Earnings Could Bring The Stock to New Highs
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
NASDAQ:ACCD

Accolade (ACCD) Stock Price, News & Analysis

$8.40
-0.18 (-2.10%)
(As of 04/16/2024 ET)
Today's Range
$8.17
$8.73
50-Day Range
$8.25
$13.92
52-Week Range
$6.33
$17.00
Volume
965,917 shs
Average Volume
718,677 shs
Market Capitalization
$650.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

Accolade MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
86.5% Upside
$15.67 Price Target
Short Interest
Bearish
4.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
-0.11mentions of Accolade in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$82,527 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.33) to ($1.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.75 out of 5 stars

Business Services Sector

84th out of 310 stocks

Business Services, Not Elsewhere Classified Industry

35th out of 87 stocks

ACCD stock logo

About Accolade Stock (NASDAQ:ACCD)

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ACCD Stock Price History

ACCD Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Accolade: Staying Bullish On Favorable Developments
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
ACCD Apr 2024 10.000 call
ACCD Apr 2024 12.500 call
Accolade Inc.
Accolade To Present at Upcoming Investor Conferences
Accolade Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Accolade Stock (NASDAQ:ACCD), Short Interest Report
PLTR Mar 2024 12.000 put
Accolade Welcomes Kindbody to Trusted Partner Ecosystem
Why Accolade (ACCD) Stock Might be a Great Pick
See More Headlines
Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/27/2023
Today
4/16/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
2/28/2025

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:ACCD
Fax
N/A
Employees
2,370
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.67
High Stock Price Target
$19.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+82.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$-459,650,000.00
Pretax Margin
-31.48%

Debt

Sales & Book Value

Annual Sales
$363.14 million
Book Value
$6.51 per share

Miscellaneous

Free Float
70,983,000
Market Cap
$664.18 million
Optionable
Optionable
Beta
2.08
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Rajeev Singh (Age 56)
    Chairman of the Board & CEO
    Comp: $778.5k
  • Mr. Robert Cavanaugh (Age 55)
    President
    Comp: $582.63k
  • Mr. Stephen H. Barnes CPA (Age 52)
    CFO & Treasurer
    Comp: $557.5k
  • Ms. Kristen Bruzek
    Senior Vice President of Operations
  • Mr. Colin McHugh (Age 45)
    Chief Accounting Officer
  • Mr. Todd Friedman
    Senior Vice President of Investor Relations
  • Mr. Richard Eskew (Age 49)
    Executive VP, General Counsel, CCO & Secretary
  • Ms. Kelsi McDonald Harris
    Chief People Officer & Senior Vice President
  • Mr. Drew Garner
    Executive Vice President of Engineering
  • Dr. Shantanu Nundy M.B.A.
    M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory Board

ACCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Accolade stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings
or view top-rated stocks.

What is Accolade's stock price target for 2024?

16 brokerages have issued 12-month price targets for Accolade's shares. Their ACCD share price targets range from $12.00 to $19.00. On average, they predict the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 86.5% from the stock's current price.
View analysts price targets for ACCD
or view top-rated stocks among Wall Street analysts.

How have ACCD shares performed in 2024?

Accolade's stock was trading at $12.01 at the start of the year. Since then, ACCD shares have decreased by 30.1% and is now trading at $8.40.
View the best growth stocks for 2024 here
.

When is Accolade's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ACCD earnings forecast
.

How can I listen to Accolade's earnings call?

Accolade will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) announced its earnings results on Thursday, April, 27th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.01. The business earned $99.03 million during the quarter, compared to analyst estimates of $99.44 million. Accolade had a negative trailing twelve-month return on equity of 27.27% and a negative net margin of 31.59%. Accolade's revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.59) EPS.

What ETFs hold Accolade's stock?
What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

When did Accolade IPO?

Accolade (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Who are Accolade's major shareholders?

Accolade's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.07%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes.
View institutional ownership trends
.

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACCD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners